Morgan Stanley Downgrades Graphite Bio to Equal-Weight, Lowers Price Target to $8
Morgan Stanley analyst Jeffrey Hung downgrades Graphite Bio (NASDAQ:GRPH) from Overweight to Equal-Weight and lowers the price target from $19 to $8.
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 39 stocks hit new 52-week lows.
Graphite Bio Q4 EPS $(0.35) Misses $(0.30) Estimate
Graphite Bio (NASDAQ:GRPH) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.30) by 16.67 percent.
RBC Capital Initiates Coverage On Graphite Bio with Sector Perform Rating, Announces Price Target of $11
RBC Capital analyst Luca Issi initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Sector Perform rating and announces Price Target of $11.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock moved upwards by 4.9% to $2.76 during Friday's after-market session. The company's market cap stands at $108.5 million.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock increased by 4.9% to $2.76 during Thursday's after-market session. The company's market cap stands at $108.5 million.
